Multinational drug corporations now put major efforts for anticancer markets in Korea.

Major multinational drug corporations have not shown any intensive efforts for the anti-cancer drug markets but recently, GSK, for instance, has declared major promotional
activities initially by taking an occasion of launching a breast cancer drug, Tykerb (lapatinib).

Tykerb was approved by the KFDA on July 30 and soon launched its market immediately upon the NHI reimbursement being grant...